[Efficacy of 188Re-herceptin radioimmunotherapy in nude mouse model of nasopharyngeal carcinoma].
OBJECTIVE
To evaluate the effect of radioimmunotherapy with (188)Re-labeled herceptin in nude mice bearing nasopharyngeal carcinoma expressing HER2/neu proto-oncogene and explore the feasibility of (188)Re-herceptin for use as a chemical therapeutic and radioimmunotherapeutic agent.


METHODS
A direct radiolabeling method was used to prepare (188)Re-Herceptin. Thirty-two nude mice bearing nasopharyngeal carcinoma were randomized into 4 groups (n=8) to receive single intravenous injection of (188)Re-Herceptin, intratumoral injection of (188)Re-Herceptin, (188)Re-nmIgG and (188)Re, respectively, all at the equivalent dose of 11.1 MBq (50 microl). Another 5 tumor-bearing mice received only intratumoral injection of 50 microl normal saline to serve as the control group. Two days after the injections, 3 mice were selected from each group (except for the control group) for biodistribution observation, and the rest mice were monitored for 4 consecutive weeks for tumor volume changes. Pathological examination of the tumor tissues was also performed.


RESULTS
The radioactivity uptake in the tumor was significantly greater whereas normal organ uptake significantly lower in the nude mice receiving intratumoral (188)Re-Herceptin injection than in those with intravenous (188)Re-Herceptin injection (11.53%ID/g vs 2.79%ID/g at 48 h). Intratumoral (188)Re-Herceptin injection caused greater inhibition of tumor growth at the 4th week as compared to the intravenous administration.


CONCLUSIONS
Intratumoral (188)Re-Herceptin administration can significantly inhibit the development of nasopharyngeal carcinoma in mice, and may potentially serve as a new clinical option of regional therapy for treating nasopharyngeal carcinoma overexpressing HER2/neu.
Li
Gui-ping
GP
Departmant of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. ligp@fimmu.com
Huang
Kai
K
Zhang
Hui
H
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D015552:Injections, Intralesional; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D009368:Neoplasm Transplantation; D016499:Radioimmunotherapy / Q000379:methods; D011868:Radioisotopes / Q000008:administration & dosage; D011897:Random Allocation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D012211:Rhenium / Q000008:administration & dosage*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011868:Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D012211:Rhenium; D000068878:Trastuzumab